Intrust Bank NA boosted its stake in Pfizer Inc. (NYSE:PFE) by 0.1% during the second quarter, Holdings Channel reports. The firm owned 65,833 shares of the biopharmaceutical company’s stock after buying an additional 60 shares during the period. Pfizer makes up about 0.9% of Intrust Bank NA’s portfolio, making the stock its 16th largest position. Intrust Bank NA’s holdings in Pfizer were worth $2,318,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Franklin Resources Inc. raised its stake in shares of Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock valued at $1,864,446,000 after buying an additional 9,005,107 shares in the last quarter. NN Investment Partners Holdings N.V. bought a new stake in shares of Pfizer during the first quarter valued at approximately $242,144,000. First Manhattan Co. raised its stake in shares of Pfizer by 127.5% in the first quarter. First Manhattan Co. now owns 8,335,663 shares of the biopharmaceutical company’s stock valued at $247,069,000 after buying an additional 4,671,057 shares in the last quarter. Jana Partners LLC raised its stake in shares of Pfizer by 46.8% in the first quarter. Jana Partners LLC now owns 13,460,304 shares of the biopharmaceutical company’s stock valued at $398,963,000 after buying an additional 4,291,486 shares in the last quarter. Finally, Sound Shore Management Inc. CT bought a new stake in shares of Pfizer during the first quarter valued at approximately $126,948,000. Institutional investors and hedge funds own 69.65% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded up 1.65% during midday trading on Friday, hitting $33.87. 27,809,992 shares of the stock were exchanged. The firm has a 50-day moving average of $34.51 and a 200-day moving average of $34.02. The company has a market capitalization of $205.44 billion, a P/E ratio of 30.03 and a beta of 0.87. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.02. The firm had revenue of $13.10 billion for the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.56 earnings per share. On average, equities analysts expect that Pfizer Inc. will post $2.46 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 3.54%. The ex-dividend date is Tuesday, November 8th. Pfizer’s payout ratio is currently 95.24%.
PFE has been the topic of several research reports. Jefferies Group set a $41.50 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Thursday, July 14th. Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.08 price target on the stock in a research report on Tuesday, August 2nd. JPMorgan Chase & Co. set a $40.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, August 3rd. Credit Suisse Group AG reissued an “outperform” rating and issued a $40.00 price target on shares of Pfizer in a research report on Monday, August 22nd. Finally, BMO Capital Markets reissued a “buy” rating and issued a $40.00 price target on shares of Pfizer in a research report on Thursday, July 21st. Ten analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.